연구성과로 돌아가기
2022 연구성과 (195 / 280)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Characterizations of Lorentzian manifolds | The focus of this paper is to characterize the Lorentzian manifolds equipped with a semi-symmetric non-metric rho-connection [briefly, (M, backward difference ~)]. The conditions for a Lorentzian manifold to be a generalized Robertson-Walker spacetime are established and vice versa. We prove that an n-dimensional compact (M, backward difference ~) is geodesically complete. We also study the properties of almost Ricci solitons and gradient almost Ricci solitons on Lorentzian manifolds and Yang pure space, respectively. Finally, we study the properties of semisymmetric (M, backward difference ~), and it is proven that (M, backward difference ~ ) is semisymmetric if and only if it is a Robertson-Walker spacetime. Published under an exclusive license by AIP Publishing. | Chaubey, S. K.; Suh, Y. J. | Univ Technol & Appl Sci, Dept Informat Technol, Sect Math, Shinas, Oman; Kyungpook Natl Univ, Dept Math, Daegu 41566, South Korea; Kyungpook Natl Univ, RIRCM, Daegu 41566, South Korea | Chaubey, S./ABB-6952-2021 | 36117508600; 7202260479 | sk22_math@yahoo.co.in;yjsuh@knu.ac.kr; | JOURNAL OF MATHEMATICAL PHYSICS | J MATH PHYS | 0022-2488 | 1089-7658 | 63 | 6 | SCIE | PHYSICS, MATHEMATICAL | 2022 | 1.3 | 63.4 | 1.77 | 2025-06-25 | 13 | 12 | ROBERTSON-WALKER SPACETIMES; RIEMANNIAN-MANIFOLDS; CURVATURE; COMPLETENESS; GEOMETRY; CONNECTION; COMPACT; SPACES; TIMES | English | 2022 | 2022-06-01 | 10.1063/5.0090046 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Near Infrared Light-Sensing Organic Light-Dependent Resistors Based on Dialkoxybenzothiadiazole-Containing Conjugated Polymer | Herein, near infrared light-sensing organic light-dependent resistors (NIR-OLDRs) is reported, that are fabricated with a planar geometry by employing poly[{3-(5-(7-methyl-5,6-bis(octyloxy)benzo[c][1,2,5]thiadiazol-4-yl)thiophen-2-yl)-6-(5-methylthiophen-2-yl)}-co-{2,5-bis(2-octyldodecyl)-2,5-dihydropyrrolo[3,4-c]pyrrole-1,4-dione}] (PDPP-8OBT) as an active layer. The PDPP-8OBT polymer, which is synthesized by the Stille coupling reaction of corresponding monomers, shows a broad absorption up to approximate to 1000 nm (wavelength) and good thermal stability with a glass transition temperature of >200 degrees C. A high-power laser diode, which emits a monochromatic NIR light (wavelength = 905 nm) for light detection and ranging (LiDAR) systems, is used to examine the characteristics of NIR-OLDRs. Results show that the present NIR-OLDRs can successfully detect the 905 nm NIR light and their electrical resistance (and photocurrent) is sensitive to the incident intensity of NIR light. In particular, for both regular and semitransparent devices, the best NIR light-sensing performances are achieved by device annealing at 150 degrees C (change of resistance = 34.5%) due to the increased crystallinity of PDPP-8OBT films. The present NIR-OLDRs exhibit excellent sensing stability upon optical on/off modulations of NIR light (905 nm). | Cho, Yeonhwa; Lee, Saebom; Kim, Taehoon; Kim, Hwajeong; Song, Dong-Ik; Kim, Youngkyoo | Kyungpook Natl Univ, Dept Chem Engn, KNU Inst Nanophoton Applicat KINPA, Organ Nanoelect Lab, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Chem Engn, Polymer Rheol Lab, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Environm Sci & Technol, Prior Res Ctr, Daegu 41566, South Korea | 57542729800; 57220102349; 57218650958; 15520531700; 7402443648; 10340424400 | ykimm@knu.ac.kr; | PHYSICA STATUS SOLIDI A-APPLICATIONS AND MATERIALS SCIENCE | PHYS STATUS SOLIDI A | 1862-6300 | 1862-6319 | 219 | 9 | SCIE | MATERIALS SCIENCE, MULTIDISCIPLINARY;PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER | 2022 | 2 | 63.4 | 0.17 | 2025-06-25 | 1 | 2 | electrical resistance; near infrared organic light-dependent resistors; photoresistors; semitransparent devices | LARGE STOKES SHIFT; PHOTOTRANSISTORS; THICKNESS; FILMS | electrical resistance; near infrared organic light-dependent resistors; photoresistors; semitransparent devices | Conjugated polymers; Crystallinity; Glass transition; High power lasers; Incident light; Infrared devices; Optical radar; Resistors; Sensitivity analysis; Electrical resistances; Light sensing; Light-dependent resistors; Near Infrared; Near infrared light; Near infrared organic light-dependent resistor; Near-infrared; Organics; Planar geometries; Semitransparent device; Electric resistance | English | 2022 | 2022-05 | 10.1002/pssa.202200068 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Status and Performance of the AMoRE-I Experiment on Neutrinoless Double Beta Decay | AMoRE is an international project to search for the neutrinoless double beta decay of Mo-100 using a detection technology consisting of magnetic microcalorimeters (MMCs) and molybdenum-based scintillating crystals. Data collection has begun for the current AMORE-I phase of the project, an upgrade from the previous pilot phase. AMoRE-I employs thirteen (CaMoO4)-Ca-48depl.-Mo-100 crystals and five (Li2MoO4)-Mo-100 crystals for a total crystal mass of 6.2 kg. Each detector module contains a scintillating crystal with two MMC channels for heat and light detection. We report the present status of the experiment and the performance of the detector modules. | Kim, H. B.; Ha, D. H.; Jeon, E. J.; Jeon, J. A.; Jo, H. S.; Kang, C. S.; Kang, W. G.; Kim, H. S.; Kim, S. C.; Kim, S. G.; Kim, S. K.; Kim, S. R.; Kim, W. T.; Kim, Y. D.; Kim, Y. H.; Kwon, D. H.; Lee, E. S.; Lee, H. J.; Lee, H. S.; Lee, J. S.; Lee, M. H.; Lee, S. W.; Lee, Y. C.; Leonard, D. S.; Lim, H. S.; Mailyan, B.; Nyanda, P. B.; Oh, Y. M.; Sari, M. B.; Seo, J. W.; Seo, K. M.; Seo, S. H.; So, J. H.; Woo, K. R.; Yoon, Y. S. | Inst Basic Sci IBS, Ctr Underground Phys, Daejeon 34126, South Korea; Seoul Natl Univ, Dept Phys & Astron, Seoul 08826, South Korea; Univ Sci & Technol UST, IBS Sch, Daejeon 34113, South Korea; Sejong Univ, Dept Phys & Astron, Seoul 05006, South Korea; Korea Res Inst Stand & Sci KRISS, Daejeon 34114, South Korea; Bandung Inst Technol, Fac Math & Nat Sci, Bandung 40132, Indonesia; Kyungpook Natl Univ, Dept Phys, Daegu 41566, South Korea | ; Lee, Yong Jae/GLR-4153-2022; Lee, Myeong Soo/C-8147-2013; Yoon, Young Soo/O-8580-2014; Kim, Hong Joo/AAE-1178-2022; Kim, Sun/G-2042-2015; Lee, Jong/A-3198-2011; Seo, Seon-Hee/M-1189-2019; Sari, Mona Berlian/HGV-2710-2022; Jo, Hyon-Suk/HGC-7070-2022; KIM, Sun Kee/IQT-8178-2023 | 55195026700; 57023186700; 57204519171; 24478376500; 35227429400; 58437336600; 24401181300; 57202103908; 7601594620; 55811804900; 57200876753; 56401942100; 57211502868; 7410207253; 57196171764; 57201795741; 57217265197; 57225012168; 23477682800; 57226402706; 57198252980; 57211265218; 57203244766; 7201953933; 57907833600; 24528726500; 57423423000; 57188969853; 57210602872; 58848723700; 56647489700; 7202469827; 35277558300; 57211276680; 35243798200 | hanbum7@snu.ac.kr;skkim@snu.ac.kr;yhk@ibs.re.kr; | JOURNAL OF LOW TEMPERATURE PHYSICS | J LOW TEMP PHYS | 0022-2291 | 1573-7357 | 209 | 5-6 | SCIE | PHYSICS, APPLIED;PHYSICS, CONDENSED MATTER | 2022 | 2 | 63.4 | 2.15 | 2025-06-25 | 23 | 24 | Neutrinoless double beta decay; Low temperature; Magnetic microcalorimeter | CRYSTAL | Low temperature; Magnetic microcalorimeter; Neutrinoless double beta decay | Calorimeters; Crystals; Neutrons; Particle detectors; Scintillation; 'current; Data collection; Detection technology; Detector module; International projects; Lows-temperatures; Magnetic microcalorimeters; Neutrinoless double-beta decays; Performance; Scintillating crystals; Temperature | English | 2022 | 2022-12 | 10.1007/s10909-022-02880-z | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Ultrasonographic Carotid Artery Flow Measurements as Predictors of Spinal Anesthesia-Induced Hypotension in Elderly Patients: A Prospective Observational Study | Background: In elderly patients, spinal anesthesia-induced hypotension (SAH) can be frequently caused by reduced pre-load and stiff ventricles. The primary purpose of this study was to investigate the ability of ultrasonograph-ic carotid artery flow measurements during the passive leg raise (PLR) test to predict SAH in elderly patients. The correlation between preoperative transthoracic echocardiography (TTE) measurements and SAH was also investigated.Material/Methods: The patients aged over 65 years scheduled for elective surgery under spinal anesthesia were recruited. Preoperative TTE was performed in all patients. Corrected carotid flow time and carotid blood flow were measured in the su-pine, semirecumbent, and PLR positions. Ultrasonographic carotid artery flow and preoperative TTE measure-ments were compared between patients who developed SAH and those who did not. Receiver operating char-acteristic (ROC) curve analysis and logistic regression analysis were used to test the association with SAH. Results: SAH occurred in 17 of 50 patients. Carotid blood flow in the semirecumbent position and preoperative mitral inflow E velocity could predict SAH, showing an area under the ROC curve of 0.754 (95% CI, 0.612-0.865) and 0.775 (95% CI, 0.634-0.881), respectively. However, according to the multivariate analysis, the independent risk factor for SAH was mitral inflow E velocity (OR 0.918, 95% CI 0.858-0.982, P=0.013).Conclusions: In elderly patients, ultrasonographic carotid artery flow measurements failed to predict the occurrence of SAH. Only preoperative mitral inflow E velocity of TTE was selected as an independent risk factor for SAH. | Kim, Hyae-Jin; Cho, Ah-Reum; Lee, Hanbit; Kim, Haekyu; Kwon, Jae -Young; Kang, Christine; Be, Soeun Jeon; Kim, Nara | Pusan Natl Univ Hosp, Med Res Inst, Dept Anesthesia & Pain Med, Busan, South Korea; Pusan Natl Univ, Sch Med, Dept Anesthesia & Pain Med, Yangsan, South Korea; Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Dent, Dept Anesthesia & Pain Med, Daegu, South Korea | Kim, Nara/J-5075-2019; Kim, Hyae Jin/HIR-5575-2022 | 56668955600; 37030745800; 57202817506; 57196215825; 7202469153; 38061496500; 57192211991; 57190426433; 57984153500 | archo@pusan.ac.kr;greenybeach@naver.com; | MEDICAL SCIENCE MONITOR | MED SCI MONITOR | 1643-3750 | 28 | SCIE | MEDICINE, RESEARCH & EXPERIMENTAL | 2022 | 3.1 | 63.6 | 0.48 | 2025-06-25 | 5 | 3 | Anesthesia; Spinal; Echocardiography; Geriatrics; Hypotension; Ultrasonography | DIASTOLIC FUNCTION; VOLUME; TIME; RESPONSIVENESS; DOPPLER; AGE | Anesthesia, Spinal; Echocardiography; Geriatrics; Hypotension; Ultrasonography | Aged; Anesthesia, Spinal; Carotid Arteries; Carotid Artery, Common; Humans; Hypotension, Controlled; Prospective Studies; atropine; bupivacaine; ephedrine; adult; aged; Article; blood pressure; body mass; carotid artery; carotid artery flow; diastolic blood pressure; echography; electrocardiography; female; flow measurement; geriatrics; heart ejection fraction; heart left ventricle; human; hypotension; induced hypotension; lumbar puncture; major clinical study; male; prospective study; pulse oximetry; receiver operating characteristic; risk factor; sensitivity and specificity; spinal anesthesia; supine position; systolic blood pressure; transthoracic echocardiography; tricuspid valve regurgitation; velocity; adverse event; carotid artery; common carotid artery; diagnostic imaging; induced hypotension | English | 2022 | 2022-11-28 | 10.12659/msm.938714 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Health-related quality of life using WHODAS 2.0 and associated factors 1 year after stroke in Korea: a multi-centre and cross-sectional study | Background: Little is known about the self-perceived level of disability of stroke survivors in the community. We aimed to characterise Health-related quality of life (HRQoL) 1 year after stroke and investigate how sociodemographic and stroke-related factors and medical adherence explain the self-perceived level of disability in a Korean stroke population. Methods: This was a multicentre cross-sectional study. A total of 382 ischaemic stroke survivors at 1 year after onset from 11 university hospitals underwent a one-session assessment, including socioeconomic variables, the modified Rankin Scale (mRS), various neurological sequelae, the Morisky, Green and Levin-Medication Adherence Questionnaire (MGL), and the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) 36-items. The relationship between disability and different variables was analysed using ordinal logistic regression. Results: The prevalence of disability based on global WHODAS 2.0 was 62.6% (mild, 41.6%; moderate, 16.0%; severe, 5.0%). The prevalence of severe disability was higher in participation in society (16.8%) and getting around (11.8%) than in other domains. Low MGL- motivation was the only factor determining a significant association between all six domains of disability after adjustment. Different predictors for specific domains were age, mRS, dysarthria, trouble seeing, cognition problems, and MGL-motivation for understanding and communicating; age, recurrent stroke, mRS, hemiplegia, facial palsy, general weakness, and MGL-motivation for getting around; age, education, mRS, hemiplegia, and MGL-motivation for self-care; education, recurrent stroke, hemiplegia, dysarthria, and MGL-motivation for getting along with people; age, education, income, mRS, hemiplegia, dysarthria, MGL-knowledge, and MGL-motivation for life activities; living without a spouse, mRS, hemiplegia, dysarthria, trouble seeing, cognition problems, general weakness, and MGL-motivation for participation in society. Conclusions: Self-perceived disability according to the WHODAS 2.0 at 1 year after stroke was highly prevalent. Each disability domain showed a different prevalence and associated factors. Interventions promoting medical adherence to motivation seemed to help achieve high HRQoL in all domains. | Lee, Hey Jean; Song, Jung-Kook; Moon, Jiyoung; Kim, Keonyeop; Park, Hyeung-Keun; Kang, Gil-Won; Shin, Jun-Ho; Kang, Jongsoo; Kim, Byoung-Gwon; Lee, Young-Hoon; Jeong, Hye Seon; Heeyoung, Lee; Lee, Won Kyung; Kim, Seongheon; Park, Young-Kwon | Kangwon Natl Univ Hosp, Gangwon Reg Cardiocerebrovasc Ctr, Dept Prevent Med, Chunchon, South Korea; Jeju Natl Univ, Jeju Natl Univ Hosp, Jeju Reg Cardiocerebrovasc Ctr, Coll Med,Dept Prevent Med, Aran 13gil 15, Jeju Si 63241, Jeju, South Korea; Kyungpook Natl Univ, Sch Med, Dept Prevent Med, Daegu, South Korea; Jeju Natl Univ, Sch Med, Dept Hlth Policy & Management, Jeju, South Korea; Chungbuk Natl Univ, Coll Med, Dept Hlth Informat & Management, Cheongju, South Korea; Chonnam Natl Univ, Sch Med, Dept Prevent Med, Gwangju, South Korea; Gyeongsang Natl Univ Hosp, Gyeongnam Reg Cerebrovasc Ctr, Dept Neurol, Jinju, South Korea; Dong A Univ Hosp, Busan Reg Cardiocerebrovasc Ctr, Pusan, South Korea; Wonkwang Univ, Wonkwang Univ Hosp, Jeonbuk Reg Cardiocerebrovasc Ctr, Dept Prevent Med,Sch Med,Wonkwang Med Sci, Iksan, Jeonbuk, South Korea; Chungnam Natl Univ Hosp, Daejeon Chungnam Reg Cardiocerebrovasc Ctr, Dept Neurol, Daejeon, South Korea; Seoul Natl Univ, Bundang Hosp, Seongnam, Gyeonggi, South Korea; Inha Univ, Inha Univ Hosp, Sch Med, Dept Prevent & Management, Incheon, South Korea; Kangwon Natl Univ, Sch Med, Chunchon, South Korea; Ulsan Univ Hosp, Prevent & Management Ctr, Ulsan Reg Cardiocerebrovasc Ctr, Ulsan, South Korea | Park, Hui/J-6839-2012 | 36450922500; 55663959300; 54407309500; 35076059600; 35215968100; 55268382300; 57199953302; 57202870606; 24281400700; 55716155400; 37031261000; 7501482409; 55556575800; 57205219384; 57216616062 | salbab@hotmail.com; | BMC NEUROLOGY | BMC NEUROL | 1471-2377 | 22 | 1 | SCIE | CLINICAL NEUROLOGY | 2022 | 2.6 | 63.9 | 0.35 | 2025-06-25 | 3 | 3 | Stroke; Disability; Quality of life; Medical adherence; Complications; Motivation; WHODAS 2.0 | OUTCOME MEASURES; ADHERENCE; INJURIES; DISEASES; BURDEN | Complications; Disability; Medical adherence; Motivation; Quality of life; Stroke; WHODAS 2.0 | Activities of Daily Living; Brain Ischemia; Cross-Sectional Studies; Disability Evaluation; Dysarthria; Hemiplegia; Humans; Quality of Life; Republic of Korea; Stroke; aged; Article; assessment of humans; asthenia; cerebrovascular accident; cognitive defect; controlled study; cross-sectional study; demography; disability; dysarthria; facial nerve paralysis; female; hemiplegia; human; ischemic stroke; Levin Medication Adherence Questionnaire; major clinical study; male; motivation; multicenter study; neurological complication; paresthesia; prevalence; quality of life; Rankin scale; self care; sociodemographics; socioeconomics; spouse; stroke survivor; university hospital; weakness; World Health Organization Disability Assessment Schedule 2.0; brain ischemia; cerebrovascular accident; clinical trial; daily life activity; dysarthria; hemiplegia; quality of life; South Korea | English | 2022 | 2022-12-24 | 10.1186/s12883-022-03032-2 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis | Introduction Myelofibrosis (MF) is characterized by ineffective and hepatosplenic extramedullary hematopoiesis due to fibrotic changes in the bone marrow and systemic manifestations due to aberrant cytokine release. Ruxolitinib (RUX) is the first JAK1/JAK2 inhibitor that is clinically approved to treat splenomegaly by ameliorating inflammatory cytokines and myeloproliferation in MF. Areas covered Patients with less advanced MF may also achieve better outcome and successful treatment with RUX. However, approximately 40% of the patients failed to achieve a stable response or have shown to be intolerant to RUX, and most of them discontinued RUX. In patients who need to discontinue or reduce the dose of RUX for any reason, RUX is known to induce a paradoxical accumulation of JAK activation loop phosphorylation that is causing RUX discontinuation syndrome (RDS). To review the topic of MF and RUX, we searched relevant literatures using PubMed. Expert opinion RUX treatment in lower IPSS risk patients who present with splenomegaly and disease-associated symptoms can be helpful. A careful discontinuation strategy with steroids may reduce the probability of RDS, and the recognition of RDS with early re-introduction of RUX is important in the treatment of severe cases of RDS. | Baek, Dong Won; Cho, Hee Jeong; Lee, Jung Min; Kim, Juhyung; Moon, Joon Ho; Sohn, Sang Kyun | Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Hematol Oncol, 130 Dongdeok Ro, Daegu 41944, South Korea | Lee, Jung-Min/L-8227-2016 | 57191874272; 57216754907; 57211561890; 58739544500; 56568642700; 13310226800 | sksohn@knu.ac.kr; | EXPERT REVIEW OF HEMATOLOGY | EXPERT REV HEMATOL | 1747-4086 | 1747-4094 | 15 | 7 | SCIE | HEMATOLOGY | 2022 | 2.8 | 63.9 | 0.06 | 2025-06-25 | 1 | 1 | Myelofibrosis; ruxolitinib; early treatment; adverse events; ruxolitinib discontinuation syndrome | HEMATOPOIETIC-CELL TRANSPLANTATION; TYROSINE KINASE JAK2; AVAILABLE THERAPY; MUTATIONAL STATUS; SINGLE-ARM; COMFORT-II; OPEN-LABEL; SAFETY; INHIBITOR; EFFICACY | adverse events; early treatment; Myelofibrosis; ruxolitinib; ruxolitinib discontinuation syndrome | Cytokines; Humans; Nitriles; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Splenomegaly; antibiotic agent; diuretic agent; hemoglobin; hydroxyurea; Janus kinase; Janus kinase 2; ruxolitinib; cytokine; nitrile; pyrazole derivative; pyrimidine derivative; ruxolitinib; abdominal distension; abdominal radiography; abnormal value; acute hypercapnic respiratory failure; adult; adverse drug reaction; aged; anemia; bleeding; blood cell count; body weight; body weight gain; body weight loss; case report; clinical article; clinical outcome; clinical practice; computer assisted tomography; contusion; cytopenia; diffuse alveolar damage; disease course; disease severity; dizziness; drug response; drug withdrawal; ECOG Performance Status; fatigue; female; fever; ground glass opacity; headache; hepatosplenomegaly; hospital readmission; human; hypoxia; International Prognostic Scoring System; leukocyte count; loss of appetite; low risk patient; lung hemorrhage; male; Medline; middle aged; myeloblast; myelofibrosis; neutropenia; null result; patient satisfaction; platelet count; pleura effusion; protein phosphorylation; repeat procedure; Review; septic shock; spleen size; systematic review; thorax pain; thorax radiography; thrombocytopenia; treatment failure; treatment refusal; treatment withdrawal; virus pneumonia; weakness; complication; myeloid metaplasia; splenomegaly | English | 2022 | 2022-07-03 | 10.1080/17474086.2022.2088499 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study | Background Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease characterized by the gradual loss of upper and lower motor neurons that leads to progressive muscle atrophy and weakness. Edaravone, a free-radical scavenger, was approved as an ALS treatment in 2015 in South Korea. Methods This study investigated the long-term effects and safety of edaravone by reviewing the medical records of 16 Korean patients with ALS who received extended edaravone between 2015 and 2021 in a single tertiary ALS center. Results Among sixteen patients, eleven patients underwent extended edaravone therapy for more than 18 cycles (72 weeks). The mean monthly changes in the revised ALS Functional Rating Scale (ALSFRS-R) were - 0.96 +/- 0.83 (0-24 weeks), - 0.70 +/- 0.76 (24-48 weeks), - 1.18 +/- 1.67 (48-72 weeks), and - 0.81 +/- 0.60 (0-72 weeks). The mean decline in forced vital capacity (FVC) was 17.4 +/- 24.1. The changes were significant in both ALSFRS-R (p < 0.001) and FVC (p = 0.048); however, the mean change in compound muscle action potential of phrenic nerves was not. Patients experienced only minor adverse events, which were well tolerated. Conclusions This study verifies previous reported outcomes of edaravone in 16 Korean ALS patients, indicating a modest effect with a favorable safety profile. | Park, Jin-Mo; Park, Donghwi; Kim, Hyung-Jun; Park, Jin-Sung | Dongguk Univ, Coll Med, Dept Neurol, Gyeongju Hosp, Gyeongju, South Korea; Univ Ulsan, Ulsan Univ Hosp, Coll Med, Dept Phys Med & Rehabil, Ulsan, South Korea; Korea Brain Res Inst KBRI, Dementia Res Grp, Daegu 41068, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Neurol, 807 Hoguk Ro, Daegu 41404, South Korea | Park, Donghwi/GYQ-6185-2022 | 55569003000; 56606561400; 57191717907; 44061744500 | neurojspark@gmail.com; | BMC NEUROLOGY | BMC NEUROL | 1471-2377 | 22 | 1 | SCIE | CLINICAL NEUROLOGY | 2022 | 2.6 | 63.9 | 0.47 | 2025-06-25 | 5 | 5 | Edaravone; Amyotrophic lateral sclerosis; Adverse effect; Safety | EFFICACY | Adverse effect; Amyotrophic lateral sclerosis; Edaravone; Safety | Amyotrophic Lateral Sclerosis; Antipyrine; Double-Blind Method; Edaravone; Humans; Neurodegenerative Diseases; Republic of Korea; norphenazone; norphenazone; phenazone; adult; amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis Functional Rating Scale; Article; clinical article; clinical outcome; drug effect; drug safety; drug tolerance; female; forced vital capacity; human; male; medical record review; muscle action potential; observational study; phrenic nerve; retrospective study; South Korea; tertiary care center; treatment duration; degenerative disease; double blind procedure; epidemiology | English | 2022 | 2022-07-14 | 10.1186/s12883-022-02788-x | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Enhanced osteogenic differentiation of mesenchymal stem cells by surface lithium modification in a sandblasted/acid-etched titanium implant | This study investigated the osteogenesis-related cell functions of osteoprogenitor cells modulated by surface chemistry modification using lithium (Li) ions in a current clinical oral implant surface in order to gain insights into the future development of titanium (Ti) implants with enhanced osteogenic capacity. Wet chemical treatment was performed to modify a sandblasted/acid-etched (SLA) Ti implant surface using Li ions. The osteogenesis-related cell response to the surface Li ion-modified SLA sample was evaluated using two kinds of murine bone marrow stem cells, bipotent ST2 cells and primary multipotent mesenchymal stem cells (MSCs). The modified surface exhibited the formation of an Li-containing Ti oxide layer with plate-like nanostructures. The Li-incorporated surface enhanced early cellular events, including spreading, focal adhesion formation and integrin mRNA expression (alpha 2, alpha 5, alpha v and beta 3), and accelerated osteogenic differentiation of bipotent ST2 cells compared with unmodified SLA surface. Surface Li modification significantly increased GSK-3 beta phosphorylation and suppressed beta-catenin phosphorylation, and promoted the subsequent osteogenic differentiation of primary MSCs. These results indicate that surface chemistry modification of SLA implants by wet chemical treatment with Li ions induces a more favorable osseointegration outcome through the promotion of the osteogenic differentiation of bone marrow MSCs via the positive regulation of GSK-3 beta and beta-catenin activity. | Park, Jin-Woo; Seo, Ji-Hun; Lee, Heon-Jin | Kyungpook Natl Univ, Sch Dent, Dept Periodontol, 2177 Dalgubeol Daero, Daegu 41940, South Korea; Korea Univ, Dept Mat Sci & Engn, Seoul, South Korea; Kyungpook Natl Univ, Sch Dent, Daegu, South Korea | ; SEO, Ji-Hun/C-2443-2011 | 56815883000; 35243312500; 36462383000 | jinwoo@mail.knu.ac.kr; | JOURNAL OF BIOMATERIALS APPLICATIONS | J BIOMATER APPL | 0885-3282 | 1530-8022 | 37 | 3 | SCIE | ENGINEERING, BIOMEDICAL;MATERIALS SCIENCE, BIOMATERIALS | 2022 | 2.9 | 64.1 | 0.33 | 2025-06-25 | 5 | 5 | Titanium implants; mesenchymal stem cells; lithium; surface modifications; osteogenic differentiation; glycogen synthase kinase 3 beta | BETA-CATENIN; BONE-FORMATION; SCAFFOLD; OSSEOINTEGRATION; PHOSPHORYLATION; BEHAVIOR; PATHWAY | glycogen synthase kinase 3β; lithium; mesenchymal stem cells; osteogenic differentiation; surface modifications; Titanium implants | Animals; beta Catenin; Cell Differentiation; Glycogen Synthase Kinase 3 beta; Interleukin-1 Receptor-Like 1 Protein; Ions; Lithium; Mesenchymal Stem Cells; Mice; Osteogenesis; Surface Properties; Titanium; Bone; Chemical modification; Flowcharting; Ions; Lithium compounds; Metal implants; Phosphorylation; Stem cells; Surface chemistry; Surface treatment; Titanium oxides; beta catenin; bone sialoprotein; lithium; transcription factor osterix; transcription factor RUNX2; beta catenin; glycogen synthase kinase 3beta; interleukin 1 receptor like 1 protein; ion; lithium; titanium; Glycogen synthase kinase; Glycogen synthase kinase 3β; Lithium ions; Mesenchymal stem cell; Osteogenesis; Osteogenic differentiation; ST2 cell; Surface-modification; Titanium implants; Wet chemical treatment; animal cell; Article; bone development; cell adhesion assay; cell differentiation; cell proliferation assay; colorimetry; confocal laser scanning microscopy; enzyme linked immunosorbent assay; field emission scanning electron microscopy; focal adhesion; gene expression; mesenchymal stem cell; mouse; mRNA expression level; nonhuman; osteoblast; osteoprogenitor cell; real time polymerase chain reaction; X ray diffraction; X ray photoemission spectroscopy; animal; bone development; cell differentiation; chemistry; metabolism; surface property; Cell culture | English | 2022 | 2022-09 | 10.1177/08853282221104242 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Electrodeposition of Pd-Ag alloy for electrical contacts | Pd-Ag alloy electrodeposit was proposed as a protective coating for electrical contacts. Before Pd alloy deposition, Ni was electroplated on a Cu substrate to limit Cu diffusion into the Pd coating. Pd-Ag alloy coatings with different Ag content were obtained using electrodeposition. Ag atomic per cent in the coatings was changed by varying the Ag mass concentration in the bath solution. Subsequently, the coated substrate experienced heat treatment at 260 degrees C for 600 s. The contact resistance of the Pd-based coatings decreased along with the increase in the Ag content, but that of heated coatings increased. Furthermore, the wettability of the Pd-based coatings with solder was enhanced owing to the increase in Ag quantity. The qualitative analysis indicated that Pd-Ag coatings inhibited Ni diffusion to the surface, which would be oxidized during heat treatment, diminishing contact resistance and wettability. | Nguyen, Yen Ngoc; Yoon, Jisun; Shin, Jiyeon; Son, Injoon | Kyungpook Natl Univ, Sch Mat Sci & Engn, Daegu 41566, South Korea | ; Nguyen, Yen/CAJ-4943-2022 | 57197767959; 57994418600; 57994575600; 9942975800 | ijson@knu.ac.kr; | SURFACE ENGINEERING | SURF ENG | 0267-0844 | 1743-2944 | 38 | 6 | SCIE | MATERIALS SCIENCE, COATINGS & FILMS | 2022 | 2.8 | 64.3 | 0.17 | 2025-06-25 | 2 | 2 | palladium; silver; alloy; electrodeposition; contact; resistance; aging | NI ALLOY; STAINLESS-STEEL; GOLD; NICKEL; NANOPARTICLES; ELECTROLESS; RESISTANCE; REDUCTION; OXIDATION; COATINGS | aging; alloy; contact; electrodeposition; palladium; resistance; silver | Contact resistance; Diffusion coatings; Electric contacts; Electrodeposition; Heat resistance; Heat treatment; Palladium alloys; Protective coatings; Silver alloys; Wetting; Alloy coatings; Alloy deposition; Contact; Cu diffusion; Cu substrate; Electrical contacts; Pd alloy; Pd-Ag alloys; Pd-based; Resistance; Electrodes | English | 2022 | 2022-06-03 | 10.1080/02670844.2022.2151335 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Enhancement of carbamazepine removal rate using Tetradesmus obliquus KNUA061 and NaOCl and utilization of the resulting biomass | Pharmaceutical and personal care products (PPCPs) are discharged into receiving water bodies mainly from sewage treatment plants. Due to the inefficient removal in conventional wastewater treatment facilities, PPCPs have become a major concern to aquatic ecosystems, water quality, and public health worldwide since they cause harmful effects on aquatic life and human even at low doses. Among the PPCPs, carbamazepine (CBZ) is one of the most commonly prescribed anticonvulsant drugs and consumed more than 1,000 tons per year. Due to its structural complexity, CBZ is known as recalcitrant compound highly stable during wastewater treatment. Consequently, it has become one of the most frequently detected pharmaceuticals in waste water, surface water, and even drinking water. In this study, Korean indigenous microalgae strains were tested as eco-friendly and cost-effective solutions for CBZ removal. Based on the preliminary biological CBZ degradation tests, Tetradesmus obliquus KNUA061 demonstrating the best CBZ removal rate was selected for further experiments. In order to increase strain KNUA061's CBZ removal efficiency, NaOCl, which is widely accepted in the water purification process, was used as an additional stimulus to induce stress conditions. At around 20 mu g L-1 CBZ, addition of 1.0 mg NaOCl resulted in approximately 20% of removal rate increase without suppressing cells growth. Roughly 90% of CBZ remained its original form and the composition of the transformed secondary metabolites was less than 10% during the biodegradation process by the microalga. Based on the results of the antioxidant enzyme activities, degree of lipid oxidation, and amino acid contents, it was concluded that the redox-defence system in microalgal cells may have been activated by the NaOCl treatment. Biomass analysis results showed that higher heating value (HHV) of strain KNUA061 biomass was higher than those of lignocellulosic energy crops suggesting that it could be utilized as a possible renewable energy source. Even though its biodiesel properties were slightly below the international standards due to the high PUFA contents, the biodiesel produced from T. obliquus KNUA061 could be used as a blending resource for transportation fuels. It was also determined that the microalgal biomass has acceptable feasibility as a sustainable dietary supplement feedstock due to its high essential amino acid contents. | Do, Jeong-Mi; Yeo, Hee-Tae; Do, Geum-Sook; Hong, Ji Won; Yoon, Ho-Sung | Kyungpook Natl Univ, Coll Nat Sci, Dept Biol, Daegu, South Korea; Kyungpook Natl Univ, Sch Life Sci, BK21 FOUR KNU Creat BioRes Grp, Daegu, South Korea; Kyungpook Natl Univ, Adv Bioresource Res Ctr, Daegu, South Korea; Kyungpook Natl Univ, Dept Hydrogen & Renewable Energy, Daegu, South Korea | 57208562245; 57224478334; 57201113384; 57201579963; 7402990205 | jwhong@knu.ac.kr;hsy@knu.ac.kr; | FRONTIERS IN ENERGY RESEARCH | FRONT ENERGY RES | 2296-598X | 10 | SCIE | ENERGY & FUELS | 2022 | 3.4 | 64.3 | 0.14 | 2025-06-25 | 1 | 2 | microalgae; emerging micropollutant; carbamazepine; sodium hypochlorite; water treatment; biomass | PERSONAL CARE PRODUCTS; WASTE-WATER TREATMENT; EFFLUENT ORGANIC-MATTER; ADVANCED OXIDATION; TREATMENT PLANTS; PHOTOCATALYTIC DEGRADATION; TRANSFORMATION PRODUCTS; EMERGING CONTAMINANTS; MARINE-PHYTOPLANKTON; SCENEDESMUS-OBLIQUUS | biomass; carbamazepine; emerging micropollutant; microalgae; sodium hypochlorite; water treatment | Amides; Aquatic ecosystems; Biodegradation; Biogas; Biomass; Blending; Chlorine compounds; Chlorophyll; Cost effectiveness; Crops; Metabolites; Microorganisms; Potable water; Quality control; Sodium; Sodium compounds; Strain; Surface waters; Wastewater treatment; Water quality; Acid content; Carbamazepine; Emerging micropollutant; Micro-algae; Micropollutants; Pharmaceutical and personal care products; Receiving water bodies; Removal rate; Sewage-treatment plants; Wastewater treatment facilities; Microalgae | English | 2022 | 2022-12-28 | 10.3389/fenrg.2022.1004613 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Performance evaluation of renewable-based sustainable micro-grid under predictive management control strategy: A case study of Gado refugee camp in Cameroon | The recent use of hybrid renewable energy systems (HRESs) is considered one of the most reliable ways to improve energy access to decentralized communities because of their techno-economic and environmental benefits. Many distant locales, such as camps in war-torn nations, lack basic necessities like power. This study proposes a remedy for power outages in these areas; by designing an HRES and a control system for monitoring, distributing, and managing the electrical power from sustainable energy sources to supply the load. Hence, providing affordable, reliable, and clean energy for all (Sustainable Development Goal 7). In this study, the feasibility and techno-economic performance of an HRES for a refugee camp was evaluated under load following (LF), cycle charging (CC), and predictive control strategy (PS). The optimization results revealed that the PS was the most suitable, as it had the lowest cost and was more eco-friendly and energy-efficient. The predictive control strategy had a 48-h foresight of the load demand and resource potential and hence could effectively manage the HRES. The total net present cost (NPC) for the electrification of this refugee camp was $3,809,822.54, and the cost of electricity generated for every kWh is $0.2018. Additionally, 991,240.32 kg of emissions can be avoided annually through the hybridization of the diesel generator under the PS. | Same, Noel Ngando; Yakub, Abdulfatai Olatunji; Nsafon, Benyoh Emmanuel Kigha; Owolabi, Abdulhameed Babatunde; Mih, Thomas Attia; Suh, Dongjun; Huh, Jeung-Soo | Kyungpook Natl Univ, Inst Global Climate Change & Energy, Dept Energy Convergence & Climate Change, Dept Convergence & Fus Syst Engn, Daegu, South Korea; Univ Buea, Coll Technol, Dept Comp Engn, Buea, Cameroon | 57895613600; 57894905100; 57895377500; 57192210107; 35173339000; 36613529600; 7102258915 | jshuh@knu.ac.kr; | FRONTIERS IN ENERGY RESEARCH | FRONT ENERGY RES | 2296-598X | 10 | SCIE | ENERGY & FUELS | 2022 | 3.4 | 64.3 | 0.49 | 2025-06-25 | 5 | 7 | hybrid renewable energy systems; predictive control strategy; techno-economic modelling; energy management; refugee camp | HYBRID ENERGY SYSTEM; TECHNOECONOMIC ANALYSIS; RURAL ELECTRIFICATION; AREA | energy management; hybrid renewable energy systems; predictive control strategy; refugee camp; techno-economic modelling | Economic analysis; Electric power system control; Energy efficiency; Energy management; Energy management systems; Renewable energy resources; Sustainable development; Energy systems; Hybrid renewable energies; Hybrid renewable energy system; Management control; Microgrid; Performances evaluation; Predictive control strategy; Refugee camps; Techno-economic model; Techno-economics; Outages | English | 2022 | 2022-09-05 | 10.3389/fenrg.2022.987495 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment | Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). This study aimed to investigate the clinical characteristics, outcomes, and associated factors of HPD using a semiautomatic volume measurement. Methods This retrospective study enrolled patients with recurrent and/or metastatic NSCLC treated with ICIs between January 2015 and August 2019 at eight tertiary centers in Korea. HPD was defined according to the tumor growth kinetics and time to treatment failure. Tumor volume was measured using a semiautomatic software. Results A total of 219 NSCLC patients with 35 HPD by volumetric measurement (HPDv) (15.9%) were enrolled. The median duration of overall survival (OS) and OS after ICI treatment (ICI-OS) were 34.5 and 18.4 months, respectively. HPDv patients had significantly worse progression-free survival (PFS) than progressive disease patients without HPDv (1.16 vs. 1.82 months, p-value <0.001). ICI-OS did not significantly differ between patients with HPDv and those without HPDv (2.66 vs. 5.4 months, p = 0.105). PD-L1 expression lower than 50%, more than three metastatic sites, neutrophil-to-lymphocyte ratio equal to or higher than 3.3, and hemoglobin level lower than 10 were found to be associated with HPDv. Conclusions There is no standardized definition of HPD. However, defining HPD in NSCLC patients treated with ICI using a semiautomatic volume measurement software is feasible. | Kim, Jehun; Kim, Taeyun; Jang, Tae Won; Kang, Hee; Kim, Mi Hyun; Yoon, Seong Hoon; Son, Choon-Hee; Lee, Hyun-Kyung; Kim, Hyun-Kuk; Lee, Shin Yup; Shin, Kyeong Choel; Han, Ji-Yeon; Kang, Eun-Ju | Kosin Univ, Dept Internal Med, Kosin Univ Gospel Hosp, Div Pulmonol,Coll Med, 262 Gamcheon Ro, Busan 49267, South Korea; Armed Forces Goyang Hosp, Dept Internal Med, Goyang Si, South Korea; Kosin Univ, Coll Med, Dept Radiol, Kosin Univ Gospel Hosp, Busan, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Div Pulmonol, Pusan, South Korea; Pusan Natl Univ, Dept Internal Med, Div Pulmonol, Yangsan Hosp, Yangsan, South Korea; Gwanghye Gen Hosp, Dept Internal Med, Div Pulmonol, Pusan, South Korea; Inje Univ, Dept Internal Med, Div Pulmonol, Busan Paik Hosp, Busan, South Korea; Inje Univ, Dept Internal Med, Div Pulmonol, Haeundae Paik Hosp, Busan, South Korea; Kyungpook Natl Univ, Dept Internal Med, Div Pulmonol, Chilgok Hosp, Daegu, South Korea; Yeungnam Univ Hosp, Dept Internal Med, Div Pulmonol, Daegu, South Korea; Inje Univ, Dept Radiol, Busan Paik Hosp, Busan, South Korea; Dong A Univ, Coll Med, Dept Radiol, Busan, South Korea | ; Kim, Taeyun/AAL-3477-2021; Kang, Eun-Ju/N-7376-2015; Kim, Young-Il/ISS-7678-2023; Kim, Woo/A-8216-2019; Han, Ji-yeon/AFU-9457-2022 | 57191899861; 57213164256; 7102426031; 55193167200; 26323727500; 55479240500; 7005976988; 57835046800; 57216619509; 49863712700; 35320479500; 57208905662; 8395421600 | jangtw22@hanmail.com; | THORACIC CANCER | THORAC CANCER | 1759-7706 | 1759-7714 | 13 | 15 | SCIE | ONCOLOGY;RESPIRATORY SYSTEM | 2022 | 2.9 | 64.4 | 0.42 | 2025-06-25 | 5 | 4 | hyperprogression; immune checkpoint inhibitor; non-small cell lung cancer; volumetry | SOLID TUMORS; IMMUNOTHERAPY; DISEASE; CHEMOTHERAPY; BLOCKADE; CRITERIA | hyperprogression; immune checkpoint inhibitor; non-small cell lung cancer; volumetry | Carcinoma, Non-Small-Cell Lung; Disease Progression; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Retrospective Studies; atezolizumab; durvalumab; hemoglobin; immune checkpoint inhibitor; nivolumab; pembrolizumab; programmed death 1 ligand 1; adult; Article; cancer growth; cancer patient; cancer recurrence; cancer survival; clinical outcome; disease association; female; hemoglobin blood level; human; major clinical study; male; middle aged; neutrophil lymphocyte ratio; non small cell lung cancer; overall survival; progression free survival; protein expression; retrospective study; software; tertiary care center; treatment failure; tumor growth; tumor volume; volumetry; disease exacerbation; drug therapy; lung tumor; non small cell lung cancer; pathology; pharmacology | English | 2022 | 2022-08 | 10.1111/1759-7714.14539 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer | This study was conducted to investigate the relationship between genetic variants in LKB1/AMPK/mTOR pathway and treatment outcomes of patients with non-small cell lung cancer (NSCLC) treated with chemotherapy. A total of 379 patients with NSCLC who underwent first-line paclitaxel-cisplatin chemotherapy was enrolled. The associations between 19 single nucleotide variants (SNVs) in the LKB1/AMPK/mTOR pathway and the chemotherapy response and overall survival (OS) were analyzed. Among the SNVs analyzed, AKT1 rs2494750G>C and TSC1 rs2809244C>A were associated with clinical outcomes after chemotherapy in multivariate analyses. The AKT1 rs2494750G>C was significantly associated with a better response to chemotherapy (adjusted odds ratio [aOR]: 1.92, 95% confidence interval [CI]: 1.02-3.62, p = 0.04). The TSC1 rs2809244C>A were significantly associated with better OS (adjusted hazard ratio [aHR]: 0.79, 95% CI: 0.62-0.99, p = 0.04). When stratified by tumor histology, AKT1 rs2494750G>C exhibited a significant association with the chemotherapy response only in adenocarcinoma and TSC1 rs2809244C>A was also significantly associated with OS only in adenocarcinoma. This result suggests that the AKT1 rs2494750G>C and TSC1 rs2809244 C>A may be useful for predicting the clinical outcome of first-line paclitaxel-cisplatin chemotherapy in NSCLC. | Ha Choi, Sun; Do, Sook Kyung; Lee, Shin Yup; Choi, Jin Eun; Kang, Hyo-Gyoung; Hong, Mi Jeong; Lee, Jang Hyuck; Lee, Won Kee; Jeong, Ji Yun; Shin, Kyung Min; Do, Young Woo; Lee, Eung Bae; Park, Ji Eun; Lee, Yong Hoon; Seo, Hyewon; Yoo, Seung Soo; Lee, Jaehee; Cha, Seung Ick; Kim, Chang Ho; Park, Jae Yong | Kyungpook Natl Univ, Dept Internal Med, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Lung Canc Ctr, Chilgok Hosp, 807 Hoguk Ro, Daegu 41404, South Korea; Kyungpook Natl Univ, Dept Biochem & Cell Biol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Cell & Matrix Res Inst, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Med Informat, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Med Res Collaborat Ctr, Daegu, South Korea; Kyungpook Natl Univ, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Pathol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Dept Radiol, Sch Med, Daegu, South Korea; Kyungpook Natl Univ, Thorac Surg, Sch Med, Daegu, South Korea | Lee, Jaehee/S-1697-2018; Lee, Yoojin/AAB-9799-2022; KIM, SUHWAN/GSE-0120-2022 | 57199723585; 56333658000; 49863712700; 37107028100; 8573181300; 55613917100; 57161223200; 22953484700; 57205472984; 7402410737; 57189600352; 55664096100; 57195437358; 57199022948; 55612130200; 56479781600; 13805476000; 35227126400; 7409873555; 58360293800 | shinyup@knu.ac.kr;jaeyong@knu.ac.kr; | THORACIC CANCER | THORAC CANCER | 1759-7706 | 1759-7714 | 13 | 23 | SCIE | ONCOLOGY;RESPIRATORY SYSTEM | 2022 | 2.9 | 64.4 | 0.32 | 2025-06-25 | 3 | 3 | chemotherapy response; LKB1; AMPK; mTOR pathway; lung cancer; survival; variant | MAMMALIAN TARGET; LKB1; SURVIVAL; RESISTANCE; KINASE; MTOR; METABOLISM; ACTIVATION; APOPTOSIS; LESSONS | chemotherapy response; LKB1/AMPK/mTOR pathway; lung cancer; survival; variant | Adenocarcinoma; AMP-Activated Protein Kinases; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; TOR Serine-Threonine Kinases; cisplatin; hamartin; hydroxymethylglutaryl coenzyme A reductase kinase kinase; mammalian target of rapamycin; paclitaxel; protein kinase LKB1; hydroxymethylglutaryl coenzyme A reductase kinase; MTOR protein, human; target of rapamycin kinase; adult; aged; AKT1 gene; AMPK signaling; Article; cancer chemotherapy; carcinogenesis; continuous infusion; controlled study; disease association; female; genetic analysis; genetic selection; genetic variability; genotyping; histology; human; major clinical study; male; middle aged; mTOR signaling; non small cell lung cancer; overall survival; population structure; prediction; primary health care; single nucleotide polymorphism; treatment outcome; treatment response; TSC1 gene; adenocarcinoma; genetics; lung tumor; metabolism; non small cell lung cancer; pathology | English | 2022 | 2022-12 | 10.1111/1759-7714.14688 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Multicenter real-world data of patients harboring rare mutations other than EGFR or ALK in advanced or metastatic non-small cell lung cancer | Background Studies on the application of targeted therapies for patients with non-small cell lung cancer (NSCLC) who harbor rare genetic mutations are ongoing. In the present study, we investigated the real-world data of NSCLC patients who harbor rare mutations. Methods We retrospectively analyzed patients with advanced or metastatic nonsquamous NSCLC aged >20 years with confirmed rare mutations (BRAF, ROS1, MET, RET, HER2, FGFR, and NTRK) from January 2015 to September 2020 at nine tertiary hospitals. In addition, we validated the lung cancer PCR panel kit in patients with confirmed mutations by NGS. Results Among 118 patients included, 88 received platinum-based chemotherapy as first-line chemotherapy. The progression-free survival of patients with BRAF, ERBB2, MET, RET, and ROS1 mutations was 10.9 months (95% confidence interval [CI]: 1.3-20.5), 5.3 months (95% CI: 3.0-7.5), 7.2 months (95% CI: 3.6-10.9), 11.4 months (95% CI: 9.2-13.6), and 10.0 months (95% CI: 3.7-16.4) respectively (p = 0.041). The median overall survival (OS) was not reached in patients with ROS1 mutations; however, in BRAF, ERBB2, MET, and RET mutant patients, median OS was 14.1 months (95% CI: 10.1-14.1), 34.5 months (95% CI: 13.2-36.9), 22.7 months (95% CI: 1.7-24.0), and 29.8 months (95% CI: 28.9-61.3), respectively (p = 0.006). Of the 27 tissue samples, 26 (96.3%) showed the same PCR panel kit result with NGS. Conclusions First-line platinum-based chemotherapy showed durable benefit in patients with advanced or metastatic nonsquamous NSCLC harboring rare genetic mutation other than EGFR or ALK. | Lee, Su Yeon; Kim, Young Chul; Lee, Kye Young; Lee, Sung Yong; Lee, Shin Yup; Lee, Min Ki; Lee, Jeong Eun; Jang, Seung Hun; Jang, Tae-Won; Choi, Chang Min | Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pulm & Crit Care Med, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea; Chonnam Natl Univ, Med Sch, Dept Internal Med, Div Pulm & Crit Care Med,Hwasun Hosp, Hwasun, South Korea; Konkuk Univ, Sch Med, Dept Pulm Med, Seoul, South Korea; Korea Univ, Coll Med, Div Pulm Allergy & Crit Care Med, Seoul, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Pusan Natl Univ, Sch Med, Dept Internal Med, Busan, South Korea; Chungnam Natl Univ, Chungnam Natl Univ Hosp, Dept Internal Med, Sch Med, Daejeon, South Korea; Hallym Univ, Dept Internal Med, Div Pulm Allergy & Crit Care Med, Sacred Heart Hosp, Anyang, South Korea; Kosin Univ, Gospel Hosp, Dept Internal Med, Busan, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea | Lee, Joo Yong/ADE-2110-2022; Kim, Yong-Joo/AAK-1840-2021; Lee, Jeong Eun/R-8689-2019 | 56216289500; 35201246200; 8720534800; 56734650000; 49863712700; 16433227400; 57209104622; 7402219050; 7102426031; 14024046800 | ccm@amc.seoul.kr; | THORACIC CANCER | THORAC CANCER | 1759-7706 | 1759-7714 | 13 | 3 | SCIE | ONCOLOGY;RESPIRATORY SYSTEM | 2022 | 2.9 | 64.4 | 0.21 | 2025-06-25 | 1 | 2 | chemotherapy; non-small cell lung cancer; oncogene; platinum | BRAF MUTATIONS; EFFICACY; PCR; NGS | Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Retrospective Studies; Young Adult; anaplastic lymphoma kinase; B Raf kinase; crizotinib; epidermal growth factor receptor; epidermal growth factor receptor 2; fibroblast growth factor receptor; pemetrexed; platinum derivative; protein Ret; scatter factor receptor; EGFR protein, human; epidermal growth factor receptor; oncoprotein; adult; advanced cancer; aged; ALK gene; Article; BRAF gene; cancer chemotherapy; clinical feature; cohort analysis; controlled study; EGFR gene; ERBB2 gene; female; FGFR gene; gene mutation; HER2 gene; high throughput sequencing; human; human tissue; lung metastasis; major clinical study; male; MET gene; non small cell lung cancer; NTRK gene; oncogene; overall survival; polymerase chain reaction; progression free survival; RET gene; retrospective study; ROS1 gene; tertiary care center; clinical trial; genetics; lung tumor; multicenter study; mutation; pathology; young adult | English | 2022 | 2022-02 | 10.1111/1759-7714.14266 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report | This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal observed plasma concentration (C-max) of alectinib and M4 were 638 and 82 ng/ml, respectively, at steady-state (day 9). These pharmacokinetic data were similar to those previously reported in patients with normal organ function. The trough plasma concentration (C-trough) of alectinib and M4 on the hemodialysis day were 562 and 66 ng/ml, respectively, identical to those on post-hemodialysis day. He remains well and in partial remission 12 months after his diagnosis. We believe that alectinib is feasible and effective for patients with ALK-rearranged non-small cell lung cancer undergoing hemodialysis. | Park, Ji Eun; Yoon, Young-Ran; Kim, Chang Ho; Lee, Jaehee | Kyungpook Natl Univ, Sch Med, Dept Internal Med, 680 Gukchaebosang Ro, Daegu 41944, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Clin Pharmacol, Daegu, South Korea | Yoon, Young-Ran/GLT-0172-2022; Lee, Jaehee/S-1697-2018; Lee, Jun Young/CAI-2335-2022 | 57195437358; 14629744500; 7409873555; 13805476000 | kimch@knu.ac.kr;jaelee@knu.ac.kr; | THORACIC CANCER | THORAC CANCER | 1759-7706 | 1759-7714 | 13 | 8 | SCIE | ONCOLOGY;RESPIRATORY SYSTEM | 2022 | 2.9 | 64.4 | 0.64 | 2025-06-25 | 6 | 6 | alectinib; ALK rearrangement; lung cancer; M4; pharmacokinetics | alectinib; ALK rearrangement; lung cancer; M4; pharmacokinetics | Adenocarcinoma of Lung; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Renal Dialysis; alectinib; alectinib; carbazole derivative; piperidine derivative; protein kinase inhibitor; adult; advanced cancer; adverse outcome; anemia; Article; brain metastasis; case report; clinical article; clinical effectiveness; clinical feature; computer assisted tomography; diabetic nephropathy; dizziness; dose response; drug blood level; drug effect; drug efficacy; follow up; gamma knife radiosurgery; hemodialysis; human; lung adenocarcinoma; lymphadenopathy; male; maximum concentration; middle aged; pharmacokinetic parameters; positron emission tomography; treatment outcome; tumor volume; weakness; hemodialysis; lung adenocarcinoma; lung tumor; non small cell lung cancer; pathology | English | 2022 | 2022-04 | 10.1111/1759-7714.14357 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: